Elicit: Interventional Trials in Metastatic Head and Neck SCC (CT, public)

Skip to main content

Interventional Trials in Metastatic Head and Neck SCC (CT, public)

Research reportView only

Loading... AlertsChat

July 29, 2025

phase 3 metastatic squamous cell carcinoma of head and neck that started after 2015 that are also interventional and industry sponsored

Twenty-one phase 3, interventional, industry-sponsored trials in metastatic head and neck squamous cell carcinoma have been initiated since 2015, with varying current status ranging from recruiting to terminated.

Abstract

Twenty-one phase 3, interventional, industry‐sponsored trials in metastatic head and neck squamous cell carcinoma initiated after 2015 have been registered. Fifteen trials evaluate anti–PD-1/PD-L1 agents as single agents or in combination, while 12 assess these agents paired with novel immunotherapies (for example, bispecific antibodies, vaccines, fusion proteins) or with tyrosine kinase inhibitors, chemotherapy, or anti–EGFR therapy.

Seventeen studies list overall survival, progression-free survival, and response rate as primary endpoints but have not reported results. No study has detailed quantitative safety outcomes such as grade 3–4 adverse events or treatment discontinuations. Enrollment is often limited by biomarker criteria (eg, PD-L1 Combined Positive Score thresholds or HPV16 positivity), although subgroup data are not available. Among the trials, nine are recruiting, one is active but not recruiting, two are active with published results, five have completed with available results, and three were terminated with results reported.

Methods

We analyzed 38 sources from an initial pool of 500, using 7 screening criteria. Each paper was reviewed for 5 key aspects that mattered most to the research question. More on methods

Papers identified with Elicit search

n = 500

Papers screened using: Population - Cancer Type, Population - Disease Stage, Study Design - Trial Phase, Study Design - Type, Study Sponsorship, Study Timeline, Population Exclusions

n = 500

Papers screened out

n = 462

Papers included for extraction

n = 38

Press enter or space to select a node.You can then use the arrow keys to move the node around. Press delete to remove it and escape to cancel.

Press enter or space to select an edge. You can then press delete to remove it or escape to cancel.

Paper search

Using your research question “phase 3 metastatic squamous cell carcinoma of head and neck that started after 2015 that are also interventional and industry sponsored”, we searched across all trials from the ClinicalTrials.gov corpus. We retrieved the 500 trials most relevant to the query.

Screening

We screened in sources based on their abstracts that met these criteria:

We considered all screening questions together and made a holistic judgement about whether to screen in each paper.

Data extraction

We asked a large language model to extract each data column below from each paper. We gave the model the extraction instructions shown below for each column.

Extract the specific study type (e.g., interventional) and exact phase (e.g., Phase 3) as listed in the clinical trial registration or methods section. If multiple phases are mentioned (e.g., Phase 2/3), record both.

Verification steps:

Acceptable responses include:

Identify the primary sponsor of the study. Look for:

Verification steps:

If multiple sponsors exist, list the primary industry sponsor. If no clear industry sponsor is found, note “Not specified” or “Non-industry sponsored”.

Extract key inclusion and exclusion criteria specific to:

Specific focus areas:

If criteria are complex, summarize the most important points. Use direct quotes from eligibility criteria when possible.

List all countries where the study is being conducted.

Extraction method:

Example format:

Describe the primary intervention in detail:

Extraction guidelines:

Example format: “Zanzalintinib (XL092) + Pembrolizumab” or “Cisplatin plus Raltitrexed concurrent with Radiotherapy”

Results

Characteristics of Included Studies

Study ID

Intervention Type

Primary Endpoints

Trial Status

Merck Sharp & Dohme LLC, 2025a

Pembrolizumab (neoadjuvant and adjuvant) + radiotherapy with or without cisplatin

Event-free survival

Active, not recruiting

AVEO Pharmaceuticals, Inc., 2025

Ficlatuzumab + cetuximab vs placebo + cetuximab

Efficacy (Overall Survival, Progression-Free Survival), safety

Recruiting

Merus N.V., 2025a

Petosemtamab + pembrolizumab vs pembrolizumab

Efficacy, safety

Recruiting

Merus N.V., 2025b

Petosemtamab vs investigator’s choice monotherapy

Efficacy, safety

Recruiting

GlaxoSmithKline and Merck Sharp & Dohme LLC, 2024a

GSK3359609 + pembrolizumab vs pembrolizumab

Efficacy (Overall Survival, Progression-Free Survival), safety

Terminated, results available

Inhibrx Biosciences, Inc., 2025

INBRX-106 + pembrolizumab vs pembrolizumab

Efficacy, safety

Recruiting

Akeso, 2024

AK112 + AK117 vs pembrolizumab

Efficacy, safety

Recruiting

Incyte Corporation and Merck Sharp & Dohme LLC, 2025

Pembrolizumab + epacadostat vs pembrolizumab vs EXTREME regimen (cetuximab, platinum, and 5-fluorouracil)

Efficacy, safety

Active, not recruiting, results available

Merck Sharp & Dohme LLC and Eisai Inc., 2025a

Pembrolizumab + lenvatinib vs pembrolizumab + placebo

Objective Response Rate, Progression-Free Survival, Overall Survival

Completed, results available

PDS Biotechnology Corp., 2025

PDS0101 + pembrolizumab vs pembrolizumab

Overall Survival, Objective Response Rate, Disease Control Rate, Duration of Response, Progression-Free Survival

Recruiting

toof

Pageof

View 12 more rows

Summary of intervention types:

Summary of trial status:

Summary of primary endpoints:


Effects

Primary Outcomes

Study ID

Overall Survival

Progression-Free Survival

Response Rate

Merck Sharp & Dohme LLC, 2025a

No mention found (non-metastatic)

No mention found

No mention found

AVEO Pharmaceuticals, Inc., 2025

No mention found

No mention found

No mention found

Merus N.V., 2025a

No mention found

No mention found

No mention found

Merus N.V., 2025b

No mention found

No mention found

No mention found

GlaxoSmithKline and Merck Sharp & Dohme LLC, 2024a

No mention found (terminated)

No mention found

No mention found

Inhibrx Biosciences, Inc., 2025

No mention found

No mention found

No mention found

Akeso, 2024

No mention found

No mention found

No mention found

Incyte Corporation and Merck Sharp & Dohme LLC, 2025

No mention found

No mention found

No mention found

Merck Sharp & Dohme LLC and Eisai Inc., 2025a

No mention found

No mention found

No mention found

PDS Biotechnology Corp., 2025

No mention found

No mention found

No mention found

toof

Pageof

View 12 more rows

Summary of findings:


Safety and Tolerability

Study ID

Grade 3-4 Adverse Events

Treatment Discontinuation

Notable Safety Findings

Merck Sharp & Dohme LLC, 2025a

No mention found

No mention found

No mention found

AVEO Pharmaceuticals, Inc., 2025

No mention found

No mention found

No mention found

Merus N.V., 2025a

No mention found

No mention found

No mention found

Merus N.V., 2025b

No mention found

No mention found

No mention found

GlaxoSmithKline and Merck Sharp & Dohme LLC, 2024a

No mention found

No mention found

No mention found

Inhibrx Biosciences, Inc., 2025

No mention found

No mention found

No mention found

Akeso, 2024

No mention found

No mention found

No mention found

Incyte Corporation and Merck Sharp & Dohme LLC, 2025

No mention found

No mention found

No mention found

Merck Sharp & Dohme LLC and Eisai Inc., 2025a

No mention found

No mention found

No mention found

PDS Biotechnology Corp., 2025

No mention found

No mention found

No mention found

toof

Pageof

View 12 more rows

Summary of findings:


Subgroup Analyses

Biomarker-Based Outcomes

Regional Variations


Discussion

References

Lead Sponsor: GlaxoSmithKline, Sponsor: None\ (2025).NCT06256588: A Study of Dostarlimab vs Placebo After Chemoradiation in Adult Participants With Locally Advanced Unresected Head and Neck Squamous Cell Carcinoma. NIH

Lead Sponsor: Sun Yat-sen University, Collaborator: Fujian Medical University Union Hospital, Collaborator: Guangzhou Panyu Central Hospital, Collaborator: The Central Hospital of Yongzhou, Collaborator: The First People's Hospital of Huaihua, and 6 more\ (2022).NCT05044117: Single-agent Capecitabine as Metronomic Chemotherapy in LAHNSCC (CMHN). NIH

Lead Sponsor: UNICANCER, Collaborator: GORTEC, Collaborator: National Cancer Institute, France, Sponsor: None\ (2024).NCT04747054: Study on the Efficacy of Treatment by Radiotherapy and Pembrolizumab in Newly Diagnosed Metastatic Head & Neck Cancers. NIH

Lead Sponsor: Exelixis, Collaborator: Merck Sharp & Dohme LLC, Sponsor: None\ (2025).NCT06082167: Study of Zanzalintinib (XL092) + Pembrolizumab vs Pembrolizumab in Subjects With PD-L1 Positive Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma. NIH

Lead Sponsor: Assiut University, Principal Investigator: doaa abd elaleem alsayed mohamed\ (2021).NCT04780750: Concurent Chemoradiotherapy in Head and Neck Cancers. NIH

Lead Sponsor: Insel Gruppe AG, University Hospital Bern, Collaborator: University of Bern, Sponsor: None\ (2024).NCT02918955: Definitive Chemo-Radiotherapy for Regionally Advanced Head and Neck Cancer With or Without Up-front Neck Dissection. NIH

Lead Sponsor: Merck Sharp & Dohme LLC, Sponsor: None\ (2025).NCT03765918: Study of Pembrolizumab Given Prior to Surgery and in Combination With Radiotherapy Given Post-surgery for Advanced Head and Neck Squamous Cell Carcinoma (MK-3475-689). NIH

Lead Sponsor: Jiangsu Cancer Institute & Hospital, Collaborator: Affiliated Hospital of Jiangnan University, Collaborator: Changzhou Cancer Hospital of Soochow University, Collaborator: The First Affiliated Hospital with Nanjing Medical University, Collaborator: Northern Jiangsu People's Hospital, and 3 more\ (2015).NCT02485548: Cisplatin Plus Raltitrexed or 5-fluorouracil Concurrent With Radiotherapy for Head and Neck Squamous Cell Cancer. NIH

Lead Sponsor: GlaxoSmithKline, Collaborator: Merck Sharp & Dohme LLC, Sponsor: None\ (2024).NCT04428333: Study of GSK3359609 With Pembrolizumab and 5-fluorouracil (5-FU)-Platinum Chemotherapy in Participants With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma. NIH

Lead Sponsor: AVEO Pharmaceuticals, Inc., Sponsor: None\ (2025).NCT06064877: A Study of Ficlatuzumab in Combination With Cetuximab in Participants With Recurrent or Metastatic (R/M) HPV Negative Head and Neck Squamous Cell Carcinoma. NIH

Lead Sponsor: Merus N.V., Sponsor: None\ (2025).NCT06525220: A Phase 3 Study to Evaluate Petosemtamab Plus Pembrolizumab vs Pembrolizumab in First-line Treatment of Head and Neck Cancer (LiGeR - HN1). NIH

Lead Sponsor: Merus N.V., Sponsor: None\ (2025).NCT06496178: A Phase 3 Study to Evaluate Petosemtamab Compared With Investigator's Choice Monotherapy in Previously Treated Head and Neck Squamous Cell Carcinoma Patients. NIH

Lead Sponsor: GlaxoSmithKline, Collaborator: Merck Sharp & Dohme LLC, Sponsor: None\ (2024).NCT04128696: Study of GSK3359609 and Pembrolizumab in Programmed Death Receptor 1-ligand 1 (PD-L1) Positive Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma. NIH

Lead Sponsor: Sinocelltech Ltd., Sponsor: None\ (2020).NCT04146402: SCT-I10A Plus Standard Chemotherapy in First-line Recurrent/ Metastatic Head and Neck Squamous Cell Carcinoma. NIH

Lead Sponsor: Barretos Cancer Hospital, Sponsor: None\ (2019).NCT03815903: Induction Chemotherapy for Locally Advanced Head and Neck Squamous Cell Carcinoma. NIH

Lead Sponsor: Inhibrx Biosciences, Inc, Sponsor: None\ (2025).NCT06295731: INBRX-106 in Combination With Pembrolizumab in First-line PD-L1 CPS≥20 HNSCC. NIH

Lead Sponsor: Akeso, Sponsor: None\ (2024).NCT06601335: A Phase 3 Study of AK112 Plus AK117 Versus Pembrolizumab in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC). NIH

Lead Sponsor: European Organisation for Research and Treatment of Cancer - EORTC, Sponsor: None\ (2021).NCT03673735: Maintenance Immune Check-point Inhibitor Following Post-operative Chemo-radiation in Subjects With HPV-negative HNSCC. NIH

Lead Sponsor: Merck Sharp & Dohme LLC, Collaborator: Eisai Inc., Sponsor: None\ (2025).NCT05523323: A Study of Pembrolizumab (MK-3475) With or Without Lenvatinib (E7080/MK-7902) as First Line (1L) Intervention in a Programmed Cell Death-ligand 1 (PD-L1) Selected Population With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC) (MK-7902-010/LEAP-010)-China Extension. NIH

Lead Sponsor: Bicara Therapeutics, Sponsor: None\ (2025).NCT06788990: FORTIFI-HN01: A Study of Ficerafusp Alfa (BCA101) or Placebo in Combination With Pembrolizumab in First-Line PD-L1-pos, R or M HNSCC. NIH

Lead Sponsor: Incyte Corporation, Collaborator: Merck Sharp & Dohme LLC, Sponsor: None\ (2025).NCT03358472: Pembrolizumab Plus Epacadostat, Pembrolizumab Monotherapy, and the EXTREME Regimen in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (KEYNOTE-669/ECHO-304). NIH

Lead Sponsor: Merck Sharp & Dohme LLC, Sponsor: None\ (2025).NCT02358031: A Study of Pembrolizumab (MK-3475) for First Line Treatment of Recurrent or Metastatic Squamous Cell Cancer of the Head and Neck (MK-3475-048/KEYNOTE-048). NIH

Lead Sponsor: Merck Sharp & Dohme LLC, Collaborator: Eisai Inc., Sponsor: None\ (2025).NCT04199104: A Study of Pembrolizumab (MK-3475) With or Without Lenvatinib (E7080/MK-7902) as First Line (1L) Intervention in a Programmed Cell Death-ligand 1 (PD-L1) Selected Population With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC) (MK-7902-010) (KEYNOTE-010). NIH

Lead Sponsor: Sun Yat-sen University, Collaborator: Hunan Cancer Hospital, Collaborator: Guilin Medical University, China, Collaborator: Jiangsu Cancer Institute & Hospital, Collaborator: Xiangya Hospital of Central South University, and 1 more\ (2024).NCT06492460: 2 Courses of Concurrent Cisplatin Chemoradiotherapy After Surgery for High-risk Head and Neck Squamous Cell Carcinoma. NIH

Lead Sponsor: Gruppo Oncologico del Nord-Ovest, Sponsor: None\ (2023).NCT05802290: NIVolumab in Subjects With Recurrent or Metastatic Platinum-refrACTORy SCCHN. NIH

Lead Sponsor: PDS Biotechnology Corp., Sponsor: None\ (2025).NCT06790966: Phase 3 Study of PDS0101 and Pembrolizumab in HPV16+ Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma. NIH

Lead Sponsor: AstraZeneca, Collaborator: Innate Pharma, Sponsor: None\ (2025).NCT04590963: Assessment of Efficacy and Safety of Monalizumab Plus Cetuximab Compared to Placebo Plus Cetuximab in Recurrent or Metastatic Head and Neck Cancer. NIH

Lead Sponsor: Lund University Hospital, Sponsor: None\ (2024).NCT06248996: a Multicentre Phase III Study of Risk-based Treatment Intensification With Hyperfractionated Radiotherapy in Head and Neck Cancer Patients. NIH

Lead Sponsor: Bristol-Myers Squibb, Collaborator: Ono Pharmaceutical Co. Ltd, Sponsor: None\ (2023).NCT02741570: Study of Nivolumab in Combination With Ipilimumab Compared to the Standard of Care (Extreme Regimen) as First Line Treatment in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck. NIH

Lead Sponsor: Institut Català d'Oncologia, Collaborator: Ferrer Internacional S.A., Sponsor: None\ (2019).NCT02715596: Changes in Body Composition After EPA Supplementation in Head and Neck Patients. NIH

Lead Sponsor: All India Institute of Medical Sciences, Principal Investigator: Aman Sharma\ (2022).NCT05187091: The SWOAR Trial Sparing of Swallowing and Aspiration Related Organs at Risk & Submandibular Gland With Intensity Modulated Radiotherapy Versus Standard IMRT in Head and Neck Squamous Cell Carcinomas. NIH

Lead Sponsor: Bristol-Myers Squibb, Sponsor: None\ (2019).NCT03386838: An Immuno-therapy Study of Nivolumab in Combination With Experimental Medication BMS-986205 Compared to Standard of Care EXTREME Regimen in First-line Recurrent/Metastatic Squamous Cell Carcinoma of Head and Neck. NIH

Lead Sponsor: AstraZeneca, Sponsor: None\ (2021).NCT02551159: Phase III Open Label Study of MEDI 4736 With/Without Tremelimumab Versus Standard of Care (SOC) in Recurrent/Metastatic Head and Neck Cancer. NIH

Lead Sponsor: Merck KGaA, Darmstadt, Germany, Sponsor: None\ (2022).NCT02383966: Phase III Trial to Assess Efficacy and Safety of Cetuximab for the Treatment of Chinese Participants With Head and Neck Cancer. NIH

Lead Sponsor: Nektar Therapeutics, Collaborator: SFJ Pharmaceuticals, Inc., Collaborator: Merck Sharp & Dohme LLC, Sponsor: None\ (2022).NCT04969861: BEMPEG With Pembrolizumab vs Pembrolizumab Alone in Patients With Metastatic or Recurrent HNSCC (PROPEL-36). NIH

Lead Sponsor: European Organisation for Research and Treatment of Cancer - EORTC, Collaborator: Swiss Cancer Institute, Collaborator: Merck Sharp & Dohme LLC, Sponsor: None\ (2025).NCT05815927: Pembrolizumab and Radiotherapy for Oligometastatic Head and Neck Cancer. NIH

Lead Sponsor: National Cancer Institute (NCI), Sponsor: None\ (2025).NCT05063552: Testing the Use of Investigational Drugs Atezolizumab and/or Bevacizumab With or Without Standard Chemotherapy in the Second-Line Treatment of Advanced-Stage Head and Neck Cancers. NIH

Lead Sponsor: BioNTech SE, Sponsor: None\ (2025).NCT04534205: A Clinical Trial Investigating the Safety, Tolerability, and Therapeutic Effects of BNT113 in Combination With Pembrolizumab Versus Pembrolizumab Alone for Patients With a Form of Head and Neck Cancer Positive for Human Papilloma Virus 16 and Expressing the Protein PD-L1. NIH

Download BIBDownload RISDownload TXT

Report

Status

Gather sources

500 sources found

Details

Screen sources

38 sources included

Details

Extract data

190 data points extracted

Details

Generate report

Save PDF

BIBLaTeX, ZoteroRISZotero, MendeleyTXTAPA BibliographyPDFPDFDOCXMicrosoft Word

Chat

Got some follow-up questions?

Sign up or sign in to chat with this report.

Back

NCT04199104: A Study of Pembrolizumab (MK-3475) With or Without Lenvatinib (E7080/MK-7902) as First Line (1L) Intervention in a Programmed Cell Death-ligand 1 (PD-L1) Selected Population With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC) (MK-7902-010) (KEYNOTE-010)

Lead Sponsor: Merck Sharp & Dohme LLC, Collaborator: Eisai Inc., Sponsor: None

NIH·

2025·

Citations unknown

ClinicalTrials

Study Type and Phase

Interventional, Phase 3

Sponsorship Details

Primary Sponsor: Merck Sharp & Dohme LLC

Collaborator: Eisai Inc.

The study is sponsored by the pharmaceutical company Merck Sharp & Dohme LLC, which serves as the lead sponsor. Eisai Inc. is listed as a collaborator, indicating a secondary sponsoring role. The Medical Director (Study Director) is from Merck Sharp & Dohme LLC, and the point of contact for clinical development is also from Merck Sharp & Dohme LLC, confirming their role as the primary industry sponsor of this clinical trial.

Participant Eligibility Criteria

Disease Stage and Metastatic Status: - Has histologically confirmed diagnosis of R/M HNSCC that is considered incurable by local therapies - Participants with newly-diagnosed HNSCC must be M1/Stage IV

Age Range: - Age: Minimum: 18 Years - No maximum age specified

Performance Status: - Has an Eastern Cooperative Oncology Group (ECOG) performance score of 0 to 1

Primary Tumor Location Requirements: - Has a primary tumor location of oropharynx, oral cavity, hypopharynx, or larynx - Primary tumor site of nasopharynx (any histology) or unknown primary tumor (including p16+ unknown primary) are not eligible

Prior Treatment Exclusions: - Has received prior therapy with lenvatinib or pembrolizumab - Has received prior therapy with an anti-PD-1, anti-PD-L1, or anti PD-L2 agent or with an agent directed to another stimulatory or co-inhibitory T-cell receptor (e.g., CTLA-4, OX-40, CD137) - Has received prior systemic anticancer therapy including investigational agents within 4 weeks before randomization - Has received prior radiotherapy within 2 weeks of start of study intervention - Had PD within 6 months of completion of curatively intended systemic treatment for locoregionally advanced HNSCC

Critical Exclusion Criteria: - Has disease that is suitable for local therapy administered with curative intent - Has a history of any contraindication or has a severe hypersensitivity to any components of pembrolizumab (≥Grade 3) or lenvatinib - Has known active central nervous system (CNS) metastases and/or carcinomatous meningitis - Has a known additional malignancy that is progressing or has required active treatment within the past 3 years

Geographical Locations

Total number of countries: 20

Countries where the study is being conducted:

- Australia - Brazil - Canada - China - France - Germany - Hungary - Italy - Japan - Korea, Republic of - Mexico - Peru - Poland - Russian Federation - Spain - Taiwan - Turkey - United Kingdom - United States(1)

Primary Intervention

The primary intervention consists of two comparative treatment arms:

Treatment Arm 1: Pembrolizumab + Lenvatinib - Pembrolizumab (MK-3475), 200 mg, every 3 weeks (Q3W) by intravenous (IV) infusion for up to 35 3-week cycles - Lenvatinib, 20 mg (two 10-mg oral capsules) administered QD

Treatment Arm 2: Pembrolizumab + Placebo - Pembrolizumab (MK-3475), 200 mg, every 3 weeks (Q3W) by intravenous (IV) infusion for up to 35 3-week cycles - Lenvatinib-matching placebo, oral capsules, administered once daily (QD)

This is a comparative study evaluating whether Pembrolizumab + lenvatinib is superior to pembrolizumab + placebo across multiple outcomes, making this a combination therapy trial versus pembrolizumab monotherapy with placebo control.

A Study of Pembrolizumab (MK-3475) With or Without Lenvatinib (E7080/MK-7902) as First Line (1L) Intervention in a Programmed Cell Death-ligand 1 (PD-L1) Selected Population With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC) (MK-7902-010) (KEYNOTE-010) (NCT04199104)

Summary

This is a study of pembrolizumab (MK-3475) with or without lenvatinib (E7080/MK-7902) as a first line intervention in a PD-L1 selected population with participants with recurrent or metastatic head and neck squamous cell carcinoma.

Hypotheses include:

Conditions & Interventions

Conditions (1)

Interventions (3)

Type Name Description Arms
DRUG Lenvatinib Lenvatinib, 20 mg (two 10-mg oral capsules) administered QD Pembrolizumab with Lenvatinib
BIOLOGICAL Pembrolizumab Pembrolizumab (MK-3475), 200 mg, every 3 weeks (Q3W) by intravenous (IV) infusion for up to 35 3-week cycles Pembrolizumab with Lenvatinib, Pembrolizumab with Placebo
DRUG Placebo Lenvatinib-matching placebo, oral capsules, administered once daily (QD) Pembrolizumab with Placebo

Eligibility

Eligibility Criteria

Inclusion Criteria:

Contraceptive use by men should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies. If the contraception requirements in the local label for any of the study interventions is more stringent than the requirements above, the local label requirements are to be followed.

Exclusion Criteria:

Locations (152)

Study Officials

Countries: Australia (3), Brazil (7), Canada (3), China (20), France (5), Germany (8), Hungary (6), Italy (6), Japan (14), Korea, Republic of (6), Mexico (5), Peru (5), Poland (8), Russian Federation (4), Spain (6), Taiwan (5), Turkey (7), United Kingdom (8), United States (26)

Facility City State/Province Country Status
California Cancer Associates for Research & Excellence ( Site 0025) Fresno California United States
California Cancer Associates for Research & Excellence ( Site 0059) San Marcos California United States
University of Colorado Cancer Center ( Site 0023) Aurora Colorado United States
University of Connecticut Health Center ( Site 0020) Farmington Connecticut United States
Memorial Regional Hospital-Memorial Cancer Institute ( Site 0069) Hollywood Florida United States
Georgia Cancer Center at Augusta University ( Site 0013) Augusta Georgia United States
Northwest Georgia Oncology Centers PC ( Site 0028) Marietta Georgia United States
University of Kansas Cancer Center ( Site 0033) Westwood Kansas United States
University of Louisville, James Graham Brown Cancer Center ( Site 0045) Louisville Kentucky United States
Dana Farber Cancer Institute ( Site 0019) Boston Massachusetts United States
University of Michigan ( Site 0064) Ann Arbor Michigan United States
Karmanos Cancer Institute ( Site 0054) Detroit Michigan United States
Henry Ford Health System ( Site 0001) Detroit Michigan United States
Washington University School of Medicine ( Site 0060) Saint Louis Missouri United States
St. Vincent Frontier Cancer Center ( Site 0008) Billings Montana United States
Oncology Hematology West, PC dba Nebraska Cancer Specialists ( Site 0053) Omaha Nebraska United States
John Theurer Cancer Center at Hackensack University Medical Center ( Site 0002) Hackensack New Jersey United States
Weill Cornell Medicine New York Presbyterian Hospital ( Site 0040) New York New York United States
SUNY Upstate Medical University ( Site 0051) Syracuse New York United States
University of North Carolina- Chapel Hill ( Site 0056) Chapel Hill North Carolina United States
Duke Cancer Center ( Site 0044) Durham North Carolina United States
Providence Portland Medical Center ( Site 0048) Portland Oregon United States
Blue Ridge Cancer Care ( Site 0015) Blacksburg Virginia United States
Inova Schar Cancer Institute ( Site 0009) Fairfax Virginia United States
Cancer Care Northwest ( Site 0017) Spokane Valley Washington United States
University of Wisconsin- Madison Carbone Cancer Center ( Site 0006) Madison Wisconsin United States
Chris OBrien Lifehouse ( Site 1002) Camperdown New South Wales Australia
St George Hospital ( Site 1001) Kogarah New South Wales Australia
Royal Adelaide Hospital ( Site 1004) Adelaide South Australia Australia
Oncocentro Ceara ( Site 0412) Fortaleza Ceara Brazil
Fundacao Sao Francisco Xavier ( Site 0409) Ipatinga Minas Gerais Brazil
ELO Pesquisa Clinica ( Site 0405) Maringa Parana Brazil
Hospital de Passo Fundo ( Site 0401) Passo Fundo Rio Grande Do Sul Brazil
Clinica LACKS ( Site 0402) Pelotas Rio Grande Do Sul Brazil
Hospital Nossa Senhora da Conceição-Centro Integrado de Pesquisa em Oncologia ( Site 0414) Porto Alegre Rio Grande Do Sul Brazil
A.C. Camargo Cancer Center ( Site 0407) Sao Paulo Brazil
Princess Margaret Cancer Centre ( Site 0200) Toronto Ontario Canada
McGill University Health Centre ( Site 0206) Montreal Quebec Canada
Centre intégré de cancérologie du CHU de Québec Université Laval, Hôpital de l’Enfant-Jésus ( Site 0 Quebec City Quebec Canada
Beijing Cancer Hospital ( Site 3314) Beining Beijing China
Peking Union Medical College Hospital ( Site 3304) Bejiing Beijing China
Chongqing Cancer Hospital ( Site 3327) Chongqing Chongqing China
Fujian Provincial Cancer Hospital ( Site 3326) Fuzhou Fujian China
Guangxi Medical University Affiliated Tumor Hospital ( Site 3322) Nanning Guangxi China
Guizhou Cancer Hospital ( Site 3330) Guiyang Guizhou China
The Third Affiliated Hospital of Harbin Medical University ( Site 3302) Harbin Heilongjiang China
Henan Cancer Hospital ( Site 3309) Zhengzhou Henan China
Wuhan Union hospital Cancer Center ( Site 3307) Wuhan Hubei China
Tongji Hospital Tongji Medical,Science & Technology ( Site 3316) Wuhan Hubei China
Hunan Cancer Hospital ( Site 3311) Changsha Hunan China
Xiangya Hospital of Central South University ( Site 3305) Changsha Hunan China
Jiangxi Cancer Hospital ( Site 3313) Nanchang Jiangxi China
Jilin Cancer Hospital ( Site 3310) Changchun Jilin China
The First Affiliated Hospital of Xi an Jiaotong University ( Site 3328) XI An Shaanxi China
Fudan University Shanghai Cancer Center ( Site 3324) Shanghai Shanghai China
Shanghai East Hospital ( Site 3300) Shanghai Shanghai China
West China Hospital of Sichuan University ( Site 3308) Chengdu Sichuan China
Tianjin Medical University Cancer Hospital ( Site 3312) Tianjin Tianjin China
Zhejiang Cancer Hospital ( Site 3303) Hangzhou Zhejiang China
Centre Leon Berard ( Site 1901) Lyon Auvergne France
Hopital de la Timone ( Site 1903) Marseille Bouches-du-Rhone France
Hopital Foch ( Site 1905) Suresnes Hauts-de-Seine France
Centre Henri Becquerel ( Site 1904) Rouen Seine-Maritime France
Gustave Roussy ( Site 1906) Villejuif Val-de-Marne France
Universitaetsklinikum Tuebingen ( Site 2108) Tuebingen Baden-Wurttemberg Germany
Universitaetsklinikum Ulm ( Site 2102) Ulm Baden-Wurttemberg Germany
Universitaetsklinikum Regensburg ( Site 2100) Regensburg Bayern Germany
Universitaetsklinikum Frankfurt ( Site 2107) Frankfurt Hessen Germany
KRH Klinikum Siloah ( Site 2103) Hannover Niedersachsen Germany
Universitaetsklinikum Koeln ( Site 2111) Koeln Nordrhein-Westfalen Germany
Universitätsklinikum Leipzig-Department for ENT ( Site 2106) Leipzig Sachsen Germany
Charite Universitätsmedizin Berlin Campus Benjamin Franklin ( Site 2112) Berlin Germany
Borsod-Abaúj-Zemplén Megyei Központi Kórház és Egyetemi Okta-Klinikai Onkológiai és Sugárterápiás Ce Miskolc Borsod-Abauj-Zemplen Hungary
Szegedi Egyetem Szent-Gyorgyi Albert Klinikai Kozpont ( Site 2207) Szeged Csongrad Hungary
Jasz Nagykun Szolnok Megyei Hetenyi Geza Korhaz Rendelointezet ( Site 2200) Szolnok Jasz-Nagykun-Szolnok Hungary
Uzsoki Utcai Korhaz ( Site 2201) Budapest Vas Hungary
Orszagos Onkologiai Intezet ( Site 2202) Budapest Hungary
Debreceni Egyetem Klinikai Kozpont ( Site 2206) Debrecen Hungary
Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia ( Site 2402) Brescia Italy
Fondazione IRCCS Istituto Nazionale dei Tumori di Milano ( Site 2400) Milano Italy
IEO Istituto Europeo di Oncologia ( Site 2406) Milano Italy
ASST Santi Paolo e Carlo - Presidio Ospedaliero San Paolo ( Site 2405) Milano Italy
Istituto Oncologico Veneto ( Site 2404) Padova Italy
ASL Liguria 2 - Ospedale San Paolo ( Site 2401) Savona Italy
Aichi Cancer Center Hospital ( Site 1113) Nagoya Aichi Japan
Nagoya University Hospital ( Site 1106) Nagoya Aichi Japan
Chiba cancer center ( Site 1110) Chiba-shi Chiba Japan
National Cancer Center Hospital East ( Site 1100) Kashiwa Chiba Japan
Hyogo Cancer Center ( Site 1112) Akashi Hyogo Japan
Kagawa University Hospital ( Site 1108) Kita-gun Kagawa Japan
Yokohama City University Hospital ( Site 1104) Yokohama Kanagawa Japan
Kindai University Hospital ( Site 1107) Osakasayama Osaka Japan
Shizuoka Cancer Center Hospital and Research Institute ( Site 1105) Sunto-gun Shizuoka Japan
National Hospital Organization Kyushu Medical Center ( Site 1111) Fukuoka Japan
Hiroshima University Hospital ( Site 1109) Hiroshima Japan
National Cancer Center Hospital ( Site 1102) Tokyo Japan
The Cancer Institute Hospital of JFCR ( Site 1103) Tokyo Japan
Tokyo Medical and Dental University Hospital ( Site 1101) Tokyo Japan
Chonnam National University Hwasun Hospital ( Site 1202) Hwasun-gun Jeonranamdo Korea, Republic of
Seoul National University Bundang Hospital ( Site 1205) Seongnam-si Kyonggi-do Korea, Republic of
Ajou University Hospital ( Site 1200) Suwon-si Kyonggi-do Korea, Republic of
Asan Medical Center ( Site 1201) Songpa-gu Seoul Korea, Republic of
Keimyung University Dongsan Hospital ( Site 1203) Daegu Taegu-Kwangyokshi Korea, Republic of
The Catholic University of Korea Eunpyeong St Mary s Hospital ( Site 1204) Seoul Korea, Republic of
Cryptex Investigación Clínica S.A. de C.V. ( Site 0608) Cuauhtémoc, Mexico City Distrito Federal Mexico
Hospital Universitario “Dr. Jose Eleuterio Gonzalez” ( Site 0602) Monterrey Nuevo Leon Mexico
Christus Muguerza Clinica Vidriera ( Site 0607) Monterrey Nuevo Leon Mexico
Centro de Investigacion y Avances Medicos Especializados -CIAME ( Site 0604) Cancun Quintana Roo Mexico
Oaxaca Site Management Organization S.C. ( Site 0603) Oaxaca Mexico
Instituto Nacional de Enfermedades Neoplasicas ( Site 0701) Lima Muni Metro De Lima Peru
Hospital Nacional Guillermo Almenara Irigoyen ( Site 0700) Lima Peru
Hospital Nacional Edgardo Rebagliati Martins ( Site 0702) Lima Peru
Hospital Nacional Arzobispo Loayza ( Site 0703) Lima Peru
Hospital Nacional Cayetano Heredia ( Site 0704) Lima Peru
Dolnoslaskie Centrum Onkologii. ( Site 2507) Wroclaw Dolnoslaskie Poland
Centrum Onkologii im prof Franciszka Lukaszczyka ( Site 2508) Bydgoszcz Kujawsko-pomorskie Poland
Szpital Specjalistyczny im. Ludwika Rydygiera w Krakowie ( Site 2502) Krakow Malopolskie Poland
Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie - P-Klinika Nowotworow Glowy i Szyi ( Site Warszawa Mazowieckie Poland
Szpital Morski im. PCK. Szpitale Pomorskie Sp. Z o.o ( Site 2504) Gdynia Pomorskie Poland
Narodowy Instytut Onkologii - Oddzial w Gliwicach ( Site 2506) Gliwice Slaskie Poland
Przychodnia Lekarska Komed ( Site 2500) Konin Wielkopolskie Poland
Szpital Kliniczny im. Heliodora Swiecickiego Uniwers Medyczn ( Site 2509) Poznan Wielkopolskie Poland
Altay Regional Oncology Dispensary ( Site 2611) Barnaul Altayskiy Kray Russian Federation
FSCC FMBA of Russia ( Site 2603) Moscow Moskva Russian Federation
Republican Clinical Oncology Dispensary of Tatarstan MoH ( Site 2609) Kazan Tatarstan, Respublika Russian Federation
Yaroslavl Regional SBIH Clinical Oncology Hospital ( Site 2605) Yaroslavl Yaroslavskaya Oblast Russian Federation
Hospital Duran i Reynals ( Site 2701) Hospitalet de Llobregat Barcelona Spain
H.U. Vall de Hebron ( Site 2700) Barcelona Spain
Hospital Universitario 12 de Octubre ( Site 2702) Madrid Spain
Hospital Universitario La Paz ( Site 2706) Madrid Spain
Hospital de Valme ( Site 2705) Sevilla Spain
Hospital Clinico Universitario Lozano Blesa ( Site 2703) Zaragoza Spain
National Cheng Kung University Hospital ( Site 1603) Taiwan Tainan Taiwan
Chang Gung Medical Foundation. Kaohsiung Branch ( Site 1604) Kaohsiung Taiwan
National Taiwan University Hospital ( Site 1600) Taipei Taiwan
MacKay Memorial Hospital ( Site 1602) Taipei Taiwan
Taipei Veterans General Hospital ( Site 1601) Taipei Taiwan
Hacettepe Universitesi Tip Fakultesi ( Site 2805) Ankara Turkey
Ankara Sehir Hastanesi ( Site 2802) Ankara Turkey
Trakya Universitesi Tip Fakultesi ( Site 2801) Edirne Turkey
Medipol Universite Hastanesi ( Site 2800) Istanbul Turkey
Ege Universitesi Tip Fakultesi Hastanesi ( Site 2804) Izmir Turkey
Medical Park Izmir Hospital ( Site 2807) Izmir Turkey
Inonu Universitesi Turgut Ozal Tip Merkezi ( Site 2803) Malatya Turkey
Aberdeen Royal Infirmary ( Site 2905) Aberdeen Aberdeen City United Kingdom
Guy’s Hospital in London ( Site 2908) London London, City Of United Kingdom
Royal Marsden NHS Foundation Trust ( Site 2910) London London, City Of United Kingdom
Mount Vernon Cancer Centre ( Site 2902) Northwood London, City Of United Kingdom
Royal Marsden Hospital ( Site 2904) Sutton London, City Of United Kingdom
Nottingham City Hospital ( Site 2907) Nottingham Nottinghamshire United Kingdom
Taunton and Somerset Hospital ( Site 2900) Taunton Somerset United Kingdom
Christie NHS Foundation Trust ( Site 2903) Manchester United Kingdom

Oversight & Regulatory

Data Monitoring Committee: Yes

FDA Regulation

Results

Participant Flow

Study Groups: 2

Overall Study

Milestone FG000 FG001
STARTED 256 255
Treated 254 253
Received Second Course 2 0
COMPLETED 0 0
NOT COMPLETED 256 255
Withdrawals

Death

Baseline Characteristics

Age, Continuous

Characteristic Pembrolizumab + Lenvatinib Pembrolizumab + Placebo Total
64.0 (8.8) 62.7 (9.6) 63.4 (9.2)

Sex: Female, Male

Characteristic Pembrolizumab + Lenvatinib Pembrolizumab + Placebo Total
Female 37 42 79
Male 219 213 432

Ethnicity (NIH/OMB)

Characteristic Pembrolizumab + Lenvatinib Pembrolizumab + Placebo Total
Hispanic or Latino 33 43 76
Not Hispanic or Latino 205 198 403
Unknown or Not Reported 18 14 32

Race (NIH/OMB)

Characteristic Pembrolizumab + Lenvatinib Pembrolizumab + Placebo Total
American Indian or Alaska Native 2 7 9
Asian 67 80 147
Native Hawaiian or Other Pacific Islander 0 0 0
Black or African American 2 2 4
White 168 147 315
More than one race 17 19 36
Unknown or Not Reported 0 0 0

Programmed Cell Death Ligand 1 (PD-L1) Tumor Expression

Characteristic Pembrolizumab + Lenvatinib Pembrolizumab + Placebo Total
<50% 192 191 383
>=50% 64 64 128

Human Papilloma Virus (HPV) Status

Characteristic Pembrolizumab + Lenvatinib Pembrolizumab + Placebo Total
Positive 57 58 115
Negative 199 197 396

Eastern Cooperative Oncology Group (ECOG Status of 0 vs 1)

Characteristic Pembrolizumab + Lenvatinib Pembrolizumab + Placebo Total
ECOG 0 122 115 237
ECOG 1 134 140 274

Outcome Measures

Primary Outcomes (3)

Objective Response Rate (ORR) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as Assessed by Blinded Independent Central Review (BICR)

ORR is defined as the percentage of participants who had a Complete Response (CR: Disappearance of all target lesions) or a Partial Response (PR: At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters) per RECIST 1.1 modified to follow a maximum of 10 target lesions and a maximum of 5 target lesions per organ. The percentage of participants who experienced a CR or PR based on modified RECIST 1.1 is presented.

Time Frame: Up to ~ 37 months | Units: Percentage of participants | Type: NUMBER

Measurement Pembrolizumab + Lenvatinib Pembrolizumab + Placebo
Value 46.9 [40.6, 53.2] 27.5 [22.1, 33.4]
Statistical Analyses
Progression Free Survival (PFS) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as Assessed by Blinded Independent Central Review (BICR).

PFS is defined as the time from randomization to the first documented progressive disease (PD) or death due to any cause, whichever occurs first. Per RECIST 1.1, PD was defined as ≥20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of ≥5 mm. Note: The appearance of one or more new lesions is also considered PD.

Time Frame: Up to ~ 37 months | Units: Months | Type: MEDIAN

Measurement Pembrolizumab + Lenvatinib Pembrolizumab + Placebo
Value 7.0 [5.6, 8.0] 2.8 [2.6, 4.1]
Statistical Analyses
Overall Survival (OS)

OS is the time from randomization to death due to any cause.

Time Frame: Up to ~ 37 months | Units: Months | Type: MEDIAN

Measurement Pembrolizumab + Lenvatinib Pembrolizumab + Placebo
Value 15.0 [13.2, 17.0] 17.9 [13.8, 21.6]
Statistical Analyses

Secondary Outcomes (3)

Duration of Response (DOR)

For participants who demonstrate a confirmed complete response (CR: Disappearance of all target lesions) or confirmed Partial Response (PR: At least a 30% decrease in the sum of diameters of target lesions) per RECIST 1.1, DOR is defined as the time from first documented evidence of CR or PR until disease progression or death.

Time Frame: Up to ~ 37 months | Units: Months | Type: MEDIAN

Measurement Pembrolizumab + Lenvatinib Pembrolizumab + Placebo
Value 10.1 [8.3, 13.9] NA [11.9, NA]
Percentage of Participants Who Experienced an Adverse Event (AE)

An adverse event (AE) is defined as any unfavorable and unintended sign including an abnormal laboratory finding, symptom or disease associated with the use of a medical treatment or procedure, regardless of whether it is considered related to the medical treatment or procedure, that occurs during the course of the study.

Time Frame: Up to ~ 37 months | Units: Percentage of Participants | Type: NUMBER

Measurement Pembrolizumab + Lenvatinib Pembrolizumab + Placebo
Value 99.21 96.84
Percentage of Participants Who Discontinued Study Drug Due to an AE

Time Frame: Up to ~ 34 months | Units: Percentage of Participants | Type: NUMBER

Measurement Pembrolizumab + Lenvatinib Pembrolizumab + Placebo
Value 43.7 15.02

Adverse Events

Reporting Threshold: 5

Time Frame: Up to ~ 37 months

All-cause mortality (ACM) was analyzed in all randomized participants. Safety analyses were conducted in all randomized participants who received at least 1 dose of study intervention. Per protocol, disease progression of cancer under study was not considered an AE unless considered related to study treatment. Thus, MedDRA 26.0 preferred terms “Neoplasm progression”, “Malignant neoplasm progression” and “Disease progression” not related to the drug are excluded.

Event Summary

Group Deaths Serious Events Other Events
Pembrolizumab + Lenvatinib First Course 152/256 (59.4%) 152/254 (59.8%) 244/254 (96.1%)
Pembrolizumab + Placebo 138/255 (54.1%) 89/253 (35.2%) 221/253 (87.4%)
Pembrolizumab + Lenvatinib Second Course 0/2 (0.0%) 0/2 (0.0%) 2/2 (100.0%)
Total 290/513 (56.5%) 241/509 (47.3%) 467/509 (91.7%)

Serious Adverse Events (200)

Event Pembrolizumab + Lenvatinib First Course (n=254) Pembrolizumab + Placebo (n=253) Pembrolizumab + Lenvatinib Second Course (n=2)
Anaemia 2 (0.8%) 0 (0.0%) 0 (0.0%)
Febrile bone marrow aplasia 1 (0.4%) 0 (0.0%) 0 (0.0%)
Acute left ventricular failure 0 (0.0%) 1 (0.4%) 0 (0.0%)
Acute myocardial infarction 4 (1.6%) 0 (0.0%) 0 (0.0%)
Atrial fibrillation 1 (0.4%) 0 (0.0%) 0 (0.0%)
Bradyarrhythmia 0 (0.0%) 1 (0.4%) 0 (0.0%)
Cardiac arrest 2 (0.8%) 1 (0.4%) 0 (0.0%)
Cardiac failure 2 (0.8%) 0 (0.0%) 0 (0.0%)
Cardiac failure acute 1 (0.4%) 0 (0.0%) 0 (0.0%)
Cardiac tamponade 1 (0.4%) 0 (0.0%) 0 (0.0%)
Cardiomyopathy 1 (0.4%) 0 (0.0%) 0 (0.0%)
Cardiovascular insufficiency 0 (0.0%) 1 (0.4%) 0 (0.0%)
Coronary artery stenosis 0 (0.0%) 1 (0.4%) 0 (0.0%)
Myocarditis 1 (0.4%) 0 (0.0%) 0 (0.0%)
Pericardial effusion 1 (0.4%) 0 (0.0%) 0 (0.0%)
Sinus node dysfunction 1 (0.4%) 0 (0.0%) 0 (0.0%)
Tracheo-oesophageal fistula 0 (0.0%) 1 (0.4%) 0 (0.0%)
Vertigo 2 (0.8%) 0 (0.0%) 0 (0.0%)
Adrenal insufficiency 2 (0.8%) 2 (0.8%) 0 (0.0%)
Hypercalcaemia of malignancy 0 (0.0%) 1 (0.4%) 0 (0.0%)
Hyperthyroidism 1 (0.4%) 0 (0.0%) 0 (0.0%)
Hypothyroidism 1 (0.4%) 0 (0.0%) 0 (0.0%)
Inappropriate antidiuretic hormone secretion 1 (0.4%) 0 (0.0%) 0 (0.0%)
Abdominal pain 2 (0.8%) 0 (0.0%) 0 (0.0%)
Colitis 1 (0.4%) 1 (0.4%) 0 (0.0%)
Constipation 0 (0.0%) 1 (0.4%) 0 (0.0%)
Diarrhoea 5 (2.0%) 0 (0.0%) 0 (0.0%)
Dysphagia 7 (2.8%) 6 (2.4%) 0 (0.0%)
Enteritis 1 (0.4%) 0 (0.0%) 0 (0.0%)
Enterocolitis 1 (0.4%) 1 (0.4%) 0 (0.0%)
Gastric haemorrhage 1 (0.4%) 0 (0.0%) 0 (0.0%)
Gastric ulcer 1 (0.4%) 0 (0.0%) 0 (0.0%)
Gastrointestinal haemorrhage 1 (0.4%) 0 (0.0%) 0 (0.0%)
Haematemesis 0 (0.0%) 1 (0.4%) 0 (0.0%)
Immune-mediated enterocolitis 1 (0.4%) 1 (0.4%) 0 (0.0%)
Intestinal obstruction 1 (0.4%) 0 (0.0%) 0 (0.0%)
Large intestine perforation 2 (0.8%) 0 (0.0%) 0 (0.0%)
Lower gastrointestinal haemorrhage 1 (0.4%) 0 (0.0%) 0 (0.0%)
Melaena 1 (0.4%) 0 (0.0%) 0 (0.0%)
Mouth haemorrhage 3 (1.2%) 1 (0.4%) 0 (0.0%)
Nausea 1 (0.4%) 1 (0.4%) 0 (0.0%)
Oesophageal stenosis 1 (0.4%) 0 (0.0%) 0 (0.0%)
Oesophagitis 1 (0.4%) 0 (0.0%) 0 (0.0%)
Oral pain 0 (0.0%) 1 (0.4%) 0 (0.0%)
Pancreatic mass 0 (0.0%) 1 (0.4%) 0 (0.0%)
Pancreatitis 0 (0.0%) 2 (0.8%) 0 (0.0%)
Pancreatitis acute 1 (0.4%) 0 (0.0%) 0 (0.0%)
Salivary duct inflammation 1 (0.4%) 0 (0.0%) 0 (0.0%)
Small intestinal obstruction 1 (0.4%) 0 (0.0%) 0 (0.0%)
Stomatitis 2 (0.8%) 0 (0.0%) 0 (0.0%)
Upper gastrointestinal haemorrhage 3 (1.2%) 1 (0.4%) 0 (0.0%)
Vomiting 4 (1.6%) 0 (0.0%) 0 (0.0%)
Asthenia 1 (0.4%) 0 (0.0%) 0 (0.0%)
Death 6 (2.4%) 3 (1.2%) 0 (0.0%)
Fatigue 2 (0.8%) 1 (0.4%) 0 (0.0%)
General physical health deterioration 2 (0.8%) 1 (0.4%) 0 (0.0%)
Malaise 1 (0.4%) 1 (0.4%) 0 (0.0%)
Pain 0 (0.0%) 1 (0.4%) 0 (0.0%)
Pyrexia 3 (1.2%) 0 (0.0%) 0 (0.0%)
Cholangitis 1 (0.4%) 0 (0.0%) 0 (0.0%)
Cholecystitis 1 (0.4%) 0 (0.0%) 0 (0.0%)
Cholecystitis acute 2 (0.8%) 0 (0.0%) 0 (0.0%)
Hepatic failure 0 (0.0%) 1 (0.4%) 0 (0.0%)
Hepatitis 1 (0.4%) 0 (0.0%) 0 (0.0%)
Hypertransaminasaemia 1 (0.4%) 0 (0.0%) 0 (0.0%)
Liver injury 1 (0.4%) 0 (0.0%) 0 (0.0%)
Hypersensitivity 0 (0.0%) 1 (0.4%) 0 (0.0%)
Abdominal abscess 1 (0.4%) 0 (0.0%) 0 (0.0%)
Abdominal infection 1 (0.4%) 0 (0.0%) 0 (0.0%)
Abscess neck 2 (0.8%) 0 (0.0%) 0 (0.0%)
Anal abscess 1 (0.4%) 0 (0.0%) 0 (0.0%)
Appendicitis 1 (0.4%) 1 (0.4%) 0 (0.0%)
Appendicitis perforated 1 (0.4%) 0 (0.0%) 0 (0.0%)
Bronchitis 1 (0.4%) 0 (0.0%) 0 (0.0%)
COVID-19 3 (1.2%) 3 (1.2%) 0 (0.0%)
COVID-19 pneumonia 1 (0.4%) 2 (0.8%) 0 (0.0%)
Cellulitis 0 (0.0%) 1 (0.4%) 0 (0.0%)
Cystitis 0 (0.0%) 1 (0.4%) 0 (0.0%)
Empyema 1 (0.4%) 0 (0.0%) 0 (0.0%)
Fournier’s gangrene 1 (0.4%) 0 (0.0%) 0 (0.0%)
Gastroenteritis 1 (0.4%) 0 (0.0%) 0 (0.0%)
Implant site infection 1 (0.4%) 0 (0.0%) 0 (0.0%)
Infected skin ulcer 1 (0.4%) 0 (0.0%) 0 (0.0%)
Lung abscess 1 (0.4%) 0 (0.0%) 0 (0.0%)
Necrotising soft tissue infection 1 (0.4%) 0 (0.0%) 0 (0.0%)
Perineal abscess 1 (0.4%) 0 (0.0%) 0 (0.0%)
Perirectal abscess 1 (0.4%) 0 (0.0%) 0 (0.0%)
Pharyngitis 1 (0.4%) 0 (0.0%) 0 (0.0%)
Pneumonia 20 (7.9%) 12 (4.7%) 0 (0.0%)
Pneumonia acinetobacter 1 (0.4%) 0 (0.0%) 0 (0.0%)
Pneumonia aspiration 7 (2.8%) 4 (1.6%) 0 (0.0%)
Pneumonia bacterial 2 (0.8%) 0 (0.0%) 0 (0.0%)
Pneumonia necrotising 1 (0.4%) 0 (0.0%) 0 (0.0%)
Pneumonia viral 1 (0.4%) 0 (0.0%) 0 (0.0%)
Rash pustular 0 (0.0%) 1 (0.4%) 0 (0.0%)
Rectal abscess 1 (0.4%) 0 (0.0%) 0 (0.0%)
Respiratory tract infection 1 (0.4%) 1 (0.4%) 0 (0.0%)
Sepsis 2 (0.8%) 1 (0.4%) 0 (0.0%)
Skin infection 1 (0.4%) 0 (0.0%) 0 (0.0%)
Stoma site infection 2 (0.8%) 0 (0.0%) 0 (0.0%)
Tracheitis 1 (0.4%) 0 (0.0%) 0 (0.0%)
Upper respiratory tract infection 3 (1.2%) 0 (0.0%) 0 (0.0%)
Urinary tract infection 1 (0.4%) 0 (0.0%) 0 (0.0%)
Urosepsis 0 (0.0%) 1 (0.4%) 0 (0.0%)
Concussion 1 (0.4%) 0 (0.0%) 0 (0.0%)
Contusion 1 (0.4%) 0 (0.0%) 0 (0.0%)
Gastrostomy tube site complication 0 (0.0%) 1 (0.4%) 0 (0.0%)
Head injury 1 (0.4%) 0 (0.0%) 0 (0.0%)
Humerus fracture 1 (0.4%) 0 (0.0%) 0 (0.0%)
Post procedural haemorrhage 2 (0.8%) 0 (0.0%) 0 (0.0%)
Radiation necrosis 0 (0.0%) 1 (0.4%) 0 (0.0%)
Stoma site haemorrhage 2 (0.8%) 0 (0.0%) 0 (0.0%)
Tracheal obstruction 0 (0.0%) 1 (0.4%) 0 (0.0%)
Vascular pseudoaneurysm 1 (0.4%) 0 (0.0%) 0 (0.0%)
Wound complication 1 (0.4%) 0 (0.0%) 0 (0.0%)
Blood urea increased 1 (0.4%) 0 (0.0%) 0 (0.0%)
Platelet count decreased 2 (0.8%) 0 (0.0%) 0 (0.0%)
Weight decreased 2 (0.8%) 0 (0.0%) 0 (0.0%)
Decreased appetite 4 (1.6%) 0 (0.0%) 0 (0.0%)
Dehydration 5 (2.0%) 0 (0.0%) 0 (0.0%)
Diabetic ketoacidosis 0 (0.0%) 1 (0.4%) 0 (0.0%)
Fulminant type 1 diabetes mellitus 1 (0.4%) 0 (0.0%) 0 (0.0%)
Hypercalcaemia 3 (1.2%) 2 (0.8%) 0 (0.0%)
Hyperglycaemia 0 (0.0%) 1 (0.4%) 0 (0.0%)
Hypoalbuminaemia 2 (0.8%) 0 (0.0%) 0 (0.0%)
Hypokalaemia 0 (0.0%) 1 (0.4%) 0 (0.0%)
Hyponatraemia 2 (0.8%) 2 (0.8%) 0 (0.0%)
Malnutrition 2 (0.8%) 1 (0.4%) 0 (0.0%)
Type 2 diabetes mellitus 0 (0.0%) 1 (0.4%) 0 (0.0%)
Arthritis 0 (0.0%) 1 (0.4%) 0 (0.0%)
Fistula 1 (0.4%) 0 (0.0%) 0 (0.0%)
Flank pain 0 (0.0%) 1 (0.4%) 0 (0.0%)
Haematoma muscle 0 (0.0%) 1 (0.4%) 0 (0.0%)
Neck pain 1 (0.4%) 0 (0.0%) 0 (0.0%)
Osteonecrosis of jaw 2 (0.8%) 0 (0.0%) 0 (0.0%)
Scleroderma 0 (0.0%) 1 (0.4%) 0 (0.0%)
Soft tissue swelling 0 (0.0%) 1 (0.4%) 0 (0.0%)
Trismus 1 (0.4%) 0 (0.0%) 0 (0.0%)
Basal cell carcinoma 1 (0.4%) 1 (0.4%) 0 (0.0%)
Bladder transitional cell carcinoma stage 0 0 (0.0%) 1 (0.4%) 0 (0.0%)
Infected neoplasm 2 (0.8%) 2 (0.8%) 0 (0.0%)
Leiomyoma 0 (0.0%) 1 (0.4%) 0 (0.0%)
Oral haemangioma 0 (0.0%) 1 (0.4%) 0 (0.0%)
Oropharyngeal squamous cell carcinoma 0 (0.0%) 1 (0.4%) 0 (0.0%)
Squamous cell carcinoma of skin 0 (0.0%) 1 (0.4%) 0 (0.0%)
Tumour haemorrhage 10 (3.9%) 8 (3.2%) 0 (0.0%)
Tumour pain 2 (0.8%) 0 (0.0%) 0 (0.0%)
Autonomic dysreflexia 1 (0.4%) 0 (0.0%) 0 (0.0%)
Cerebral haemorrhage 1 (0.4%) 0 (0.0%) 0 (0.0%)
Cerebral infarction 0 (0.0%) 1 (0.4%) 0 (0.0%)
Cerebrovascular accident 2 (0.8%) 0 (0.0%) 0 (0.0%)
Diabetic hyperosmolar coma 0 (0.0%) 1 (0.4%) 0 (0.0%)
Haemorrhagic stroke 1 (0.4%) 0 (0.0%) 0 (0.0%)
Headache 2 (0.8%) 0 (0.0%) 0 (0.0%)
Ischaemic stroke 1 (0.4%) 0 (0.0%) 0 (0.0%)
Spinal cord compression 1 (0.4%) 1 (0.4%) 0 (0.0%)
Syncope 0 (0.0%) 1 (0.4%) 0 (0.0%)
Device dislocation 3 (1.2%) 0 (0.0%) 0 (0.0%)
Device occlusion 1 (0.4%) 0 (0.0%) 0 (0.0%)
Alcohol withdrawal syndrome 0 (0.0%) 1 (0.4%) 0 (0.0%)
Confusional state 0 (0.0%) 1 (0.4%) 0 (0.0%)
Delirium 2 (0.8%) 0 (0.0%) 0 (0.0%)
Nephrotic syndrome 1 (0.4%) 0 (0.0%) 0 (0.0%)
Renal impairment 1 (0.4%) 0 (0.0%) 0 (0.0%)
Urinary retention 0 (0.0%) 1 (0.4%) 0 (0.0%)
Prostatitis 0 (0.0%) 1 (0.4%) 0 (0.0%)
Acute respiratory distress syndrome 0 (0.0%) 1 (0.4%) 0 (0.0%)
Acute respiratory failure 0 (0.0%) 1 (0.4%) 0 (0.0%)
Apnoea 0 (0.0%) 1 (0.4%) 0 (0.0%)
Aspiration 2 (0.8%) 0 (0.0%) 0 (0.0%)
Autoimmune lung disease 0 (0.0%) 1 (0.4%) 0 (0.0%)
Bronchial obstruction 1 (0.4%) 0 (0.0%) 0 (0.0%)
Bronchopleural fistula 1 (0.4%) 0 (0.0%) 0 (0.0%)
Chronic obstructive pulmonary disease 2 (0.8%) 0 (0.0%) 0 (0.0%)
Dyspnoea 5 (2.0%) 1 (0.4%) 0 (0.0%)
Epistaxis 2 (0.8%) 1 (0.4%) 0 (0.0%)
Haemoptysis 2 (0.8%) 0 (0.0%) 0 (0.0%)
Immune-mediated lung disease 1 (0.4%) 1 (0.4%) 0 (0.0%)
Laryngeal stenosis 2 (0.8%) 0 (0.0%) 0 (0.0%)
Obstructive airways disorder 0 (0.0%) 2 (0.8%) 0 (0.0%)
Oropharyngeal fistula 1 (0.4%) 0 (0.0%) 0 (0.0%)
Oropharyngeal pain 2 (0.8%) 0 (0.0%) 0 (0.0%)
Pharyngeal haemorrhage 2 (0.8%) 0 (0.0%) 0 (0.0%)
Pharyngeal inflammation 1 (0.4%) 0 (0.0%) 0 (0.0%)
Pleural effusion 1 (0.4%) 1 (0.4%) 0 (0.0%)
Pleurisy 0 (0.0%) 1 (0.4%) 0 (0.0%)
Pneumomediastinum 0 (0.0%) 1 (0.4%) 0 (0.0%)
Pneumonitis 3 (1.2%) 6 (2.4%) 0 (0.0%)
Pneumothorax 2 (0.8%) 0 (0.0%) 0 (0.0%)
Pulmonary embolism 1 (0.4%) 2 (0.8%) 0 (0.0%)
Pulmonary haemorrhage 1 (0.4%) 1 (0.4%) 0 (0.0%)
Respiratory failure 3 (1.2%) 1 (0.4%) 0 (0.0%)
Tracheal fistula 1 (0.4%) 0 (0.0%) 0 (0.0%)
Drug eruption 1 (0.4%) 0 (0.0%) 0 (0.0%)
Skin ulcer 1 (0.4%) 0 (0.0%) 0 (0.0%)
Arterial haemorrhage 1 (0.4%) 0 (0.0%) 0 (0.0%)
Embolism 1 (0.4%) 0 (0.0%) 0 (0.0%)
Hypertension 3 (1.2%) 0 (0.0%) 0 (0.0%)
Hypotension 3 (1.2%) 0 (0.0%) 0 (0.0%)
Orthostatic hypotension 1 (0.4%) 0 (0.0%) 0 (0.0%)
Total events 293 131 0

Other Adverse Events (64)

Event Pembrolizumab + Lenvatinib First Course (n=254) Pembrolizumab + Placebo (n=253) Pembrolizumab + Lenvatinib Second Course (n=2)
Anaemia 65 (25.6%) 51 (20.2%) 0 (0.0%)
Ear pain 6 (2.4%) 2 (0.8%) 1 (50.0%)
Hyperthyroidism 19 (7.5%) 10 (4.0%) 0 (0.0%)
Hypothyroidism 124 (48.8%) 43 (17.0%) 0 (0.0%)
Bowel movement irregularity 0 (0.0%) 0 (0.0%) 1 (50.0%)
Constipation 56 (22.0%) 46 (18.2%) 0 (0.0%)
Diarrhoea 71 (28.0%) 33 (13.0%) 1 (50.0%)
Dry mouth 17 (6.7%) 18 (7.1%) 0 (0.0%)
Dyspepsia 14 (5.5%) 3 (1.2%) 0 (0.0%)
Dysphagia 35 (13.8%) 14 (5.5%) 0 (0.0%)
Flatulence 2 (0.8%) 1 (0.4%) 1 (50.0%)
Nausea 62 (24.4%) 25 (9.9%) 0 (0.0%)
Oral pain 29 (11.4%) 6 (2.4%) 0 (0.0%)
Stomatitis 53 (20.9%) 12 (4.7%) 0 (0.0%)
Vomiting 33 (13.0%) 14 (5.5%) 0 (0.0%)
Asthenia 26 (10.2%) 25 (9.9%) 1 (50.0%)
Fatigue 80 (31.5%) 41 (16.2%) 1 (50.0%)
Mucosal inflammation 25 (9.8%) 7 (2.8%) 0 (0.0%)
Pyrexia 20 (7.9%) 19 (7.5%) 0 (0.0%)
COVID-19 16 (6.3%) 13 (5.1%) 0 (0.0%)
Pneumonia 25 (9.8%) 11 (4.3%) 0 (0.0%)
Urinary tract infection 13 (5.1%) 13 (5.1%) 0 (0.0%)
Alanine aminotransferase increased 36 (14.2%) 21 (8.3%) 0 (0.0%)
Amylase increased 14 (5.5%) 14 (5.5%) 0 (0.0%)
Aspartate aminotransferase increased 37 (14.6%) 23 (9.1%) 0 (0.0%)
Blood alkaline phosphatase increased 13 (5.1%) 19 (7.5%) 0 (0.0%)
Blood bilirubin increased 17 (6.7%) 7 (2.8%) 0 (0.0%)
Blood creatinine increased 26 (10.2%) 5 (2.0%) 0 (0.0%)
Blood thyroid stimulating hormone increased 16 (6.3%) 7 (2.8%) 0 (0.0%)
Lipase increased 30 (11.8%) 17 (6.7%) 0 (0.0%)
Lymphocyte count decreased 30 (11.8%) 20 (7.9%) 0 (0.0%)
Platelet count decreased 31 (12.2%) 8 (3.2%) 0 (0.0%)
Weight decreased 65 (25.6%) 39 (15.4%) 0 (0.0%)
White blood cell count decreased 16 (6.3%) 10 (4.0%) 0 (0.0%)
Decreased appetite 57 (22.4%) 23 (9.1%) 1 (50.0%)
Hypercalcaemia 11 (4.3%) 18 (7.1%) 0 (0.0%)
Hyperglycaemia 14 (5.5%) 11 (4.3%) 0 (0.0%)
Hyperkalaemia 18 (7.1%) 7 (2.8%) 0 (0.0%)
Hypoalbuminaemia 34 (13.4%) 23 (9.1%) 0 (0.0%)
Hypokalaemia 22 (8.7%) 9 (3.6%) 0 (0.0%)
Hypomagnesaemia 22 (8.7%) 7 (2.8%) 0 (0.0%)
Hyponatraemia 44 (17.3%) 28 (11.1%) 0 (0.0%)
Hypophosphataemia 14 (5.5%) 3 (1.2%) 0 (0.0%)
Arthralgia 40 (15.7%) 18 (7.1%) 0 (0.0%)
Musculoskeletal chest pain 8 (3.1%) 3 (1.2%) 1 (50.0%)
Neck pain 18 (7.1%) 8 (3.2%) 0 (0.0%)
Dizziness 13 (5.1%) 8 (3.2%) 0 (0.0%)
Headache 32 (12.6%) 16 (6.3%) 0 (0.0%)
Insomnia 25 (9.8%) 12 (4.7%) 0 (0.0%)
Haematuria 13 (5.1%) 7 (2.8%) 0 (0.0%)
Proteinuria 62 (24.4%) 16 (6.3%) 0 (0.0%)
Cough 40 (15.7%) 23 (9.1%) 1 (50.0%)
Dysphonia 23 (9.1%) 4 (1.6%) 0 (0.0%)
Dyspnoea 25 (9.8%) 14 (5.5%) 0 (0.0%)
Haemoptysis 10 (3.9%) 10 (4.0%) 1 (50.0%)
Oropharyngeal pain 28 (11.0%) 8 (3.2%) 0 (0.0%)
Pneumonitis 11 (4.3%) 10 (4.0%) 1 (50.0%)
Productive cough 17 (6.7%) 6 (2.4%) 0 (0.0%)
Dry skin 15 (5.9%) 8 (3.2%) 0 (0.0%)
Palmar-plantar erythrodysaesthesia syndrome 36 (14.2%) 2 (0.8%) 0 (0.0%)
Pruritus 27 (10.6%) 29 (11.5%) 0 (0.0%)
Rash 34 (13.4%) 23 (9.1%) 0 (0.0%)
Hypertension 117 (46.1%) 24 (9.5%) 0 (0.0%)
Hypotension 14 (5.5%) 7 (2.8%) 1 (50.0%)

Additional Information

PI is Sponsor Employee: No

Point of Contact

IPD Sharing Statement

IPD Sharing: YES

https://trialstransparency.msdclinicaltrials.com/pdf/ProcedureAccessClinicalTrialData.pdf

URL: https://externaldatasharing-msd.com/

Documents & Links

Study Documents

Document Type Date Size Filename
Protocol, SAP, Prot_SAP 2023-10-19 1,429,816 bytes Prot_SAP_000.pdf

References (1)